 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | CBA-1535 / Chiome Biosci
Biomarker, New P1 trial: A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - Jun 12, 2025
P1, N=70, Recruiting, Sponsor: Chiome Bioscience Inc.
- CBA-1535 / Chiome Biosci
Preclinical characterization of CBA-1535, a novel bi-specific tribody, with two binding sites to 5T4 and one site to CD3? (Section 23; Poster Board #15) - Mar 14, 2023 - Abstract #AACR2023AACR_5100;
These results provide the strong rationale for further clinical evaluation ofCBA-1535 in 5T4 positive tumors. CBA-1535 is now under the phase 1 trial in Japan (jRCT2031210708), with 2 parts, the monotherapy and the combination with Pembrolizumab.
- | CBA-1535 / Chiome Biosci
Preclinical, Journal: Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo. (Pubmed Central) - Sep 11, 2022
CBA-1535 is now under the phase 1 trial in Japan (jRCT2031210708), with 2 parts, the monotherapy and the combination with Pembrolizumab. The novel tribodies have the potential to become strong and safe therapeutic drugs, allowing to reduce also the cost of production as one single molecule contains three different specificities including the anti-TAA, anti-CD3 and anti-IC binding arms.